Equity Overview
Price & Market Data
Price: $1.54
Daily Change: -$0.24 / 15.58%
Daily Range: $1.30 - $1.93
Market Cap: $188,930,176
Daily Volume: 2,252,789
Performance Metrics
1 Week: -4.79%
1 Month: -3.64%
3 Months: -4.79%
6 Months: 1.92%
1 Year: 67.81%
YTD: 128.4%
Company Details
Employees: 9
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It is also developing TZLS-501, a fully human mAb targeting the IL-6 receptor for use in the treatment of inflammatory and oncology indications. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.